ImMucin which targets the SP domain of the MUC1 cancer antigen. According to the National Cancer Institute, MUC1 is the second most promising cancer antigen, and it is expressed by over 90% of tumor types. MUC1 has therefore been heavily targeted, but with little success to date. Vaxil however, has developed its VaxHitTM immunotherapy platform specifically in order to target antigens like MUC1 in a unique and significantly advantageous manner.
Unlike other MUC1 clinical programs which target the extracellular soluble Tandem Repeat Array (TRA) domain on MUC1, ImMucin is directed against the less explored cellular located SP domain with its unique antigenic (MUC1 specificity) and immunodominant properties. In preclinical studies including the use of MUC1 transgenic mice, ImMucin and its internal 9-mer epitopes manifested superior immunity, anti-tumor activity vs. a selection of other MUC1-TRA derived products. In addition, ImMucin’s epitopes were the most abundant MUC1 epitope in tens of non-vaccinated cancer patients.